How does dysregulated histone acetylation contribute to cancer, and how can this be leveraged for cancer treatment?
DOI:
https://doi.org/10.58445/rars.1763Keywords:
cancer, histone acetylation, HDACAbstract
Histone Deacetylases or HDACs play a significant part in the advancement of cancer. HDACs control the epigenome through acetylation. The epigenome is responsible for changes in gene expression outside of the nucleotide sequence of DNA. HDACs play a considerable part in the epigenome because they are specific proteins with the ability to deacetylate histones. The reason why HDACs are so important is because when specific HDACs are overexpressed they have the ability to suppress particular cancer suppressing genes. As a result, HDAC overexpression can promote cancer formation. However in recent years there has been research into HDAC inhibitors which impact the function of HDACs and restore the normal function of cancer preventing genes. Some HDAC inhibitors are specifically used towards certain HDACs while others have an impact on a wide range of HDACs. HDAC inhibitors could prove to be helpful to the advancement of cancer treatment due to their potential in more targeted treatment and their potential in combination treatments as well.
References
Aldana-Masangkay GI, Sakamoto KM. The role of HDAC6 in cancer. J Biomed Biotechnol. 2011;2011:875824.
Bocheng Wu, Shaghayegh Fathi, Shanee Mortley, Mahir Mohiuddin, Young C. Jang, Adegboyega K. Oyelere, Pyrimethamine conjugated histone deacetylase inhibitors: Design, synthesis and evidence for triple negative breast cancer selective cytotoxicity, Bioorganic & Medicinal Chemistry, Volume 28, Issue 6,2020,115345,ISSN 0968-0896,https://doi.org/10.1016/j.bmc.2020.115345.
de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J. 2003 Mar 15;370(Pt 3):737-49. doi: 10.1042/BJ20021321. PMID: 12429021; PMCID: PMC1223209.
Garcia-Martinez L, Zhang Y, Nakata Y, Chan HL, Morey L. Epigenetic mechanisms in breast cancer therapy and resistance. Nat Commun. 2021 Mar 19;12(1):1786. doi: 10.1038/s41467-021-22024-3. PMID: 33741974; PMCID: PMC7979820.
Han, H., Feng, X., He, T., Wu, Y., He, T., Yue, Z., & Zhou, W. (2024). Discussion on structure classification and regulation function of histone deacetylase and their inhibitor. Chemical Biology & Drug Design, 103, e14366. https://doi.org/10.1111/cbdd.14366
Hwang ES, Song SB. Nicotinamide is an inhibitor of SIRT1 in vitro, but can be a stimulator in cells. Cell Mol Life Sci. 2017 Sep;74(18):3347-3362. doi: 10.1007/s00018-017-2527-8. Epub 2017 Apr 17. PMID: 28417163; PMCID: PMC11107671.
Kawai, H., Li, H., Avraham, S., Jiang, S., and Avraham, H. K. (2003). Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor α. International Journal of Cancer, 107(3), 353-358. https://doi.org/10.1002/ijc.11403
L.A.L. Maués, G.M. Alves, N.M.G. Couto, B.J.M. da Silva, M.S.P. Arruda, B.M. Macchi, C.B.C. Sena, A.F. Prado, M.E. Crespo-Lopez, E.O. Silva, J.L.M. do Nascimento,Flavonoids from the Amazon plant Brosimum acutifolium induce C6 glioma cell line apoptosis by disrupting mitochondrial membrane potential and reducing AKT phosphorylation,Biomedicine & Pharmacotherapy,Volume 113,2019,108728,ISSN 0753-3322, https://doi.org/10.1016/j.biopha.2019.108728.
Liu SS, Wu F, Jin YM, Chang WQ, Xu TM. HDAC11: a rising star in epigenetics. Biomed Pharmacother. 2020 Nov;131:110607. doi: 10.1016/j.biopha.2020.110607. Epub 2020 Aug 22. PMID: 32841898.
Maccallini C, Ammazzalorso A, De Filippis B, Fantacuzzi M, Giampietro L, Amoroso R. HDAC Inhibitors for the Therapy of Triple Negative Breast Cancer. Pharmaceuticals. 2022; 15(6):667. https://doi.org/10.3390/ph15060667
Qin G, Li Y, Xu X, Wang X, Zhang K, Tang Y, Qiu H, Shi D, Zhang C, Long Q, Lee K, Zhai Q, Wang S, Chen M, Deng W. Panobinostat (LBH589) inhibits Wnt/β-catenin signaling pathway via upregulating APCL expression in breast cancer. Cell Signal. 2019 Jul;59:62-75. doi: 10.1016/j.cellsig.2019.03.014. Epub 2019 Mar 14. PMID: 30880222.
Rifaï K, Judes G, Idrissou M, Daures M, Bignon Y, Penault-Llorca F and Bernard-Gallon D SIRT1-dependent epigenetic regulation of H3 and H4 histone acetylation in human breast cancer, oncotarget. 2018; 30661-30678
Shahbazian, M., & Grunstein, D. (2007). Functions of Site-Specific Histone Acetylation and Deacetylation. Annual Review of Biochemistry. https://pubmed.ncbi.nlm.nih.gov/17362198/
Wawruszak A, Borkiewicz L, Okon E, Kukula-Koch W, Afshan S, Halasa M. Vorinostat (SAHA) and Breast Cancer: An Overview. Cancers (Basel). 2021 Sep 19;13(18):4700. doi: 10.3390/cancers13184700. PMID: 34572928; PMCID: PMC8468501.
Xue K, Gu JJ, Zhang Q, Mavis C, Hernandez-Ilizaliturri FJ, Czuczman MS, Guo Y. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents. J Cancer Res Clin Oncol. 2016 Feb;142(2):379-87. doi: 10.1007/s00432-015-2026-y. Epub 2015 Aug 28. PMID: 26314218.
Zhao H, Zhang XM, Xiao S, Wu ZR, Shi YJ, Xie MJ. HDAC11 is related to breast cancer prognosis and inhibits invasion and proliferation of breast cancer cells. Int J Clin Exp Pathol. 2023 Jul 15;16(7):172-183. PMID: 37559686; PMCID: PMC10408431.
Downloads
Posted
Categories
License
Copyright (c) 2024 Charlotte Tang
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.